Zhang et al (2018) show that topical treatment with a GLUT1 inhibitor alleviates psoriasis pathology similar to the results we obtain by using inhibitors directed at glutaminolysis (CB839) and metabolic cross‐talk (aspartate uptake [TFB‐TBOA]). The gene discussed is SLC2A1; the disease is psoriasis.